Regional therapy trials in peritoneal metastases: The path to standardization of care for gastric cancer

2021 ◽  
Vol 125 (1) ◽  
pp. 64-68
Author(s):  
Brian Badgwell
Keyword(s):  
Gastric Cancer ◽  
Peritoneal Metastases ◽  
Regional Therapy

Hypericin-Mediated Intraperitoneal Photodynamic Diagnostics and Therapy in Peritoneal Metastases of Gastric Cancer (Hypericin-PDT; EudraCT-Number 2015-005277-21; NCT-02840331)

2018 ◽  
Vol 56 (08) ◽  
pp. e341-e341
Author(s):  
C Yurttas ◽  
P Birk ◽  
M Löffler ◽  
I Königsrainer ◽  
A Königsrainer ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Peritoneal Metastases ◽  
Photodynamic Diagnostics ◽  
Diagnostics And Therapy

scholarly journals Pathological complete response after intraperitoneal paclitaxel and systemic combined chemotherapy in a patient with peritoneal metastases from gastric cancer: a case report

2020 ◽  
Vol 6 (1) ◽  
Author(s):  
Yoshiyuki Meguro ◽  
Hironori Yamaguchi ◽  
Joji Kitayama ◽  
Rihito Kanamaru ◽  
Shiro Matsumoto ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Case Report ◽  
Pathological Complete Response ◽  
Complete Response ◽  
Peritoneal Metastases ◽  
Combined Chemotherapy

scholarly journals Randomized phase II/III study of 5-fluorouracil/l-leucovorin versus 5-fluorouracil/l-leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108/WJOG7312G)

2020 ◽  
Vol 23 (4) ◽  
pp. 677-688 ◽  
Author(s):  
Takako Eguchi Nakajima ◽  
Kensei Yamaguchi ◽  
Narikazu Boku ◽  
Ichinosuke Hyodo ◽  
Junki Mizusawa ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Phase Ii ◽  
Peritoneal Metastases ◽  
Randomized Phase Ii

RT-PCR Increases Detection of Submicroscopic Peritoneal Metastases in Gastric Cancer and Has Prognostic Significance

2012 ◽  
Vol 16 (5) ◽  
pp. 889-896 ◽  
Author(s):  
Joyce Wong ◽  
Kaitlyn Jane Kelly ◽  
Arjun Mittra ◽  
Mithat Gonen ◽  
Peter Allen ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Prognostic Significance ◽  
Peritoneal Metastases ◽  
Rt Pcr

scholarly journals Neoadjuvant intraperitoneal chemotherapy followed by radical surgery and HIPEC in patients with very advanced gastric cancer and peritoneal metastases: report of an initial experience in a western single center

2018 ◽  
Vol 16 (1) ◽  
Author(s):  
Bianca Escorel Costa Fava ◽  
Wilson Luiz da Costa ◽  
Maria Luiza L. Medeiros ◽  
Marina Sonagli ◽  
Héber Salvador de Castro Ribeiro ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Intraperitoneal Chemotherapy ◽  
Radical Surgery ◽  
Peritoneal Metastases ◽  
Initial Experience ◽  
Single Center

Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Metastases (CYTO-CHIP study): A Propensity Score Analysis

2019 ◽  
Vol 37 (23) ◽  
pp. 2028-2040 ◽  
Author(s):  
Pierre-Emmanuel Bonnot ◽  
Guillaume Piessen ◽  
Vahan Kepenekian ◽  
Evelyne Decullier ◽  
Marc Pocard ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Propensity Score ◽  
Intraperitoneal Chemotherapy ◽  
Cytoreductive Surgery ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
Peritoneal Cancer Index ◽  
Peritoneal Metastases ◽  
Recurrence Free Survival ◽  
Free Survival ◽  
Peritoneal Cancer

PURPOSE Gastric cancer (GC) with peritoneal metastases (PMs) is a poor prognostic evolution. Cytoreductive surgery (CRS) yields promising results, but the impact of hyperthermic intraperitoneal chemotherapy (HIPEC) remains controversial. Here we aimed to compare outcomes between CRS-HIPEC versus CRS alone (CRSa) among patients with PMs from GC. PATIENTS AND METHODS From prospective databases, we identified 277 patients with PMs from GC who were treated with complete CRS with curative intent (no residual nodules > 2.5 mm) at 19 French centers from 1989 to 2014. Of these patients, 180 underwent CRS-HIPEC and 97 CRSa. Tumor burden was assessed using the peritoneal cancer index. A Cox proportional hazards regression model with inverse probability of treatment weighting (IPTW) based on propensity score was used to assess the effect of HIPEC and account for confounding factors. RESULTS After IPTW adjustment, the groups were similar, except that median peritoneal cancer index remained higher in the CRS-HIPEC group (6 v 2; P = .003). CRS-HIPEC improved overall survival (OS) in both crude and IPTW models. Upon IPTW analysis, in CRS-HIPEC and CRSa groups, median OS was 18.8 versus 12.1 months, 3- and 5-year OS rates were 26.21% and 19.87% versus 10.82% and 6.43% (adjusted hazard ratio, 0.60; 95% CI, 0.42 to 0.86; P = .005), and 3- and 5-year recurrence-free survival rates were 20.40% and 17.05% versus 5.87% and 3.76% ( P = .001), respectively; the groups did not differ regarding 90-day mortality (7.4% v 10.1%, respectively; P = .820) or major complication rate (53.7% v 55.3%, respectively; P = .496). CONCLUSION Compared with CRSa, CRS-HIPEC improved OS and recurrence-free survival, without additional morbidity or mortality. When complete CRS is possible, CRS-HIPEC may be considered a valuable therapy for strictly selected patients with limited PMs from GC.

Prevention and Treatment of Peritoneal Metastases from Gastric Cancer

2019 ◽  
pp. 277-291
Author(s):  
Mei Li M. Kwong ◽  
Chukwuemeka Ihemelandu ◽  
Paul H. Sugarbaker
Keyword(s):  
Gastric Cancer ◽  
Peritoneal Metastases ◽  
Prevention And Treatment

Perioperative chemotherapy and cytoreductive surgery with versus without HIPEC in gastric cancer with limited peritoneal metastases: A randomized phase III study (GASTRIPEC).

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. TPS4132-TPS4132 ◽  
Author(s):  
Beate Rau ◽  
Markus Loeffler ◽  
Horst-Guenther Rau ◽  
Udo Sulkowski ◽  
Jan Kuhlmann ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cytoreductive Surgery ◽  
Peritoneal Metastases ◽  
Phase Iii ◽  
Perioperative Chemotherapy ◽  
Phase Iii Study

Analysis Of Risk Factors Of Positive Peritoneal Cytology In Patients Treated For Gastric Cancer – Preliminary Report*

2015 ◽  
Vol 87 (10) ◽  
Author(s):  
Radosław Lisiecki ◽  
Arkadiusz Spychała ◽  
Katarzyna Pater ◽  
Dawid Murawa
Keyword(s):  
Gastric Cancer ◽  
Surgical Treatment ◽  
Cancer Cells ◽  
Peritoneal Cavity ◽  
Peritoneal Metastases ◽  
Histological Type ◽  
Gastric Body ◽  
Peritoneal Cytology ◽  
Positive Cytology ◽  
Positive Peritoneal Cytology

AbstractPresence of free gastric cancer cells in the peritoneal cavity of patients who underwent surgical treatment for gastric cancer is a negative prognostic factor and caused rapid disease recurrence, manifested as peritoneal metastases.Positive peritoneal cytology despite lack of visible peritoneal metastases was regarded as M1 class in the TNM classification (7was to analyze factors associated with positive peritoneal cytology and identify groups of patients in whom diagnostic laparoscopy plus peritoneal lavage in the diagnostic process could affect therapeutic decisions.The study enrolled patients with gastric cancer who underwent surgical treatment at the Department of Surgery, Wielkopolskie Oncology Center in Poznań. During the laparotomy, after opening of the peritoneal cavity, 200 ml of physiological saline at 37°C was administered in the tumor region. After this fluid was mixed, 100 ml of lavage fluid was collected. This fluid was subsequently spun many times to obtain sediment for cytology and immunohistochemistry investigation using anti-BerEp-4, CK 7/20, and B72.3.Results of peritoneal cytology were analyzed jointly with clinical factors – patient’s age, sex and pathology factors – tumor invasion, involvement of lymph nodes, histological grade, histological type according to Lauren and localization of the cancer in the stomach.Analysis of the peritoneal fluid for presence of free cancer cells was done in 51 patients. Positive peritoneal cytology was found in 12 (23.5%) patients. In the group of patients with positive cytology, all patients had T3/T4 tumors and all were found to have lymph node metastases, while G3 cancer was found in 83.3% of patients. In patients with positive cytology, diffuse gastric cancer according to Lauren predominated (9 of 12 patients, 75%), while in patients with negative cytology – intestinal type (20 of 39 patients, 51.2%). In the group of patients with positive histology, the whole stomach was involved by the cancer process in 7 of 12 patients (58.3%), while in the group with negative histology, in 29 of 39 patients the tumor was located in the gastric body and prepyloric part (74.4%).Based on this study we can conclude that determinants of positive peritoneal cytology include: tumor stage T3/T4, N+, G3, cancer located in the whole stomach, diffuse histological type according to Lauren.

Sign in / Sign up

Export Citation Format

Share Document